Sofia Heigis, CEO of Oncopeptides, recently visited the Biostock studio to present the company, its’ ambitions for Pepaxti in Europe and rest of the world and also outline the company´s strategic pivot into a multi-indication global biotech, spearheaded by its glioblastoma project.
The presentation is followed by a Q&A session with Jonas Söderström, managing partner at Biostock.
You can also watch a longer interview with Sofia here.